CONCOMITANT TREATMENT WITH ATEZOLIZUMAB AND ENZALUTAMIDE FOR METASTASTIC NON-SMALL-CELL LUNG CANCER AND METASTASTIC PROSTATE CANCER: A CASE REPORT

Melgarejo Ortuño A1, Bautista Sanz MP1, Sánchez de Torre A2, Bernal Hertfelder E2, Apezteguía Fernández CA1, Amor García MA1, De Cáceres Velasco C1, Moreno Díaz R3.

1Servicio de Farmacia. Hospital Universitario Infanta Cristina. Parla, Spain
2Servicio de Oncología Médica. Hospital Universitario Infanta Cristina. Parla, Spain

BACKGROUND AND IMPORTANCE

No cases have been reported in clinical practice with experience in the management of patients with lung and prostate cancer under concomitant treatment with atezolizumab and enzalutamide.

AIM AND OBJECTIVE

This was a descriptive, retrospective clinical case. The data (diagnostic tests, therapy and clinical course) were obtained by review of electronic medical records. Adherence was evaluate using medication possession ratio (MPR).

MATERIALS AND METHODS

RESULTS

CONCLUSION AND RELEVANCE

No cases have been reported in the literature, but there is one phase III trial, Imbassador250, which at least reports concomitant administration of the two drugs for prostate cancer. Given the favourable safety data and the efficacy data reported for both treatments for their corresponding indications, enzalutamide is initiated while treatment with atezolizumab is maintained. No toxicity from the treatments has been reported. The patient has maintained both treatments to the present day, maintaining clinical response for both tumours. The patient has shown 100% adherence to oral and intravenous treatment.

This is the first case report with evidence of efficacy of concomitant treatment with atezolizumab for lung cancer and enzalutamide for prostate cancer, with no additional toxicity.

It is important to report these cases in real clinical practice, because these conditions will not be present in clinical trials.